Aurora Cannabis (TSE:ACB) Rating Increased to Strong-Buy at Atb Cap Markets

Atb Cap Markets upgraded shares of Aurora Cannabis (TSE:ACB) from a hold rating to a strong-buy rating in a report published on Wednesday,Zacks.com reports.

A number of other brokerages have also commented on ACB. TD Securities upgraded shares of Aurora Cannabis to a “strong-buy” rating in a research note on Thursday, December 12th. ATB Capital decreased their target price on shares of Aurora Cannabis from C$11.00 to C$8.50 in a research note on Tuesday, December 17th. Three analysts have rated the stock with a hold rating, one has issued a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of C$5.85.

Aurora Cannabis Stock Performance

Shares of ACB opened at C$8.63 on Wednesday. Aurora Cannabis has a 12 month low of C$3.84 and a 12 month high of C$12.85. The business’s fifty day simple moving average is C$6.08 and its two-hundred day simple moving average is C$7.18. The company has a current ratio of 3.76, a quick ratio of 2.48 and a debt-to-equity ratio of 16.95. The company has a market cap of C$471.72 million, a price-to-earnings ratio of -13.70 and a beta of 2.71.

Aurora Cannabis (TSE:ACB) last released its quarterly earnings data on Wednesday, November 6th. The company reported C$0.05 EPS for the quarter, topping the consensus estimate of C($0.30) by C$0.35. Aurora Cannabis had a negative return on equity of 6.13% and a negative net margin of 11.53%. During the same period in the prior year, the business posted ($0.70) earnings per share. Research analysts anticipate that Aurora Cannabis will post -0.22 earnings per share for the current fiscal year.

Aurora Cannabis Company Profile

Aurora Cannabis, headquartered in Edmonton, Canada, cultivates and sells medicinal and recreational cannabis through a portfolio of brands that includes Aurora, CanniMed, Daily Special, MedReleaf, and San Rafael ’71. Although the company primarily operates in Canada, it has expanded internationally through medical cannabis exporting agreements or cultivation facilities in more than 20 countries.